ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca(2+)‐signalling dysregulation or toxicity in pancreatic acinar cells

BACKGROUND AND PURPOSE: Many cancer cells depend on anti‐apoptotic B‐cell lymphoma 2 (Bcl‐2) proteins for their survival. Bcl‐2 antagonism through Bcl‐2 homology 3 (BH3) mimetics has emerged as a novel anti‐cancer therapy. ABT‐199 (Venetoclax), a recently developed BH3 mimetic that selectively inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakubowska, Monika A, Kerkhofs, Martijn, Martines, Claudio, Efremov, Dimitar G, Gerasimenko, Julia V, Gerasimenko, Oleg V, Petersen, Ole H, Bultynck, Geert, Vervliet, Tim, Ferdek, Pawel E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Themed Section: Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887725/
https://www.ncbi.nlm.nih.gov/pubmed/30266036
http://dx.doi.org/10.1111/bph.14505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887725/
https://www.ncbi.nlm.nih.gov/pubmed/30266036
http://dx.doi.org/10.1111/bph.14505

Ejemplares similares